Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

Bone Marrow Transplantation volume 54, pages 1089–1093 (2019)Cite this article

Subjects

Abstract

Primary plasma cell leukemia (pPCL) is a rare and aggressive variant of multiple myeloma (MM) with poor long-term survival after cytotoxic chemotherapy. Many novel drugs have revolutionized the treatment algorithms for MM. The impact of targeted therapy, both pre- and post-autologous stem cell transplant (auto-HCT) remains an area of ongoing interest. In this study, we report outcomes post auto-HCT for pPCL and the impact of maintenance therapy posttransplant with novel agents.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a surveillance, epidemiology, and end results database analysis between 1973 and 2004. Cancer. 2009;115:5734–9. https://doi.org/10.1002/cncr.24700.

    Article  PubMed  Google Scholar 

  2. Tiedemann RE, Gonzalez-Paz N, Kyle RA, Santana-Davila R, Price-Troska T, Van Wier SA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22:1044–52. https://doi.org/10.1038/leu.2008.4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Mahindra A, Kalaycio ME, Vela-Ojeda J, Vesole DH, Zhang MJ, Li P, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the center for international blood and marrow transplant research. Leukemia. 2012;26:1091–7. https://doi.org/10.1038/leu.2011.312.

    Article  CAS  PubMed  Google Scholar 

  4. Musto P, Pagano L, Petrucci MT, Morabito F, Caravita T, Di Raimondo F, et al. Primary plasma cell leukemia in the era of new drugs: has something changed? Crit Rev Oncol Hematol. 2012;82:141–9. https://doi.org/10.1016/j.critrevonc.2011.04.005.

    Article  PubMed  Google Scholar 

  5. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32:587–600. https://doi.org/10.1200/JCO.2013.48.7934.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, et al. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma, Myeloma & Leuk. 2011;11:507–11. https://doi.org/10.1016/j.clml.2011.06.010.

    Article  Google Scholar 

  7. Vela-Ojeda J, Garcia-Ruiz Esparza MA, Rosas-Cabral A, Padilla-Gonzalez Y, Garcia-Chavez J, Tripp-Villanueva F, et al. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Ann Hematol. 2002;81:362–7. https://doi.org/10.1007/s00277-002-0480-5.

    Article  CAS  PubMed  Google Scholar 

  8. D'Arena G, Valentini CG, Pietrantuono G, Guariglia R, Martorelli MC, Mansueto G, et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA multiple myeloma working party. Ann Oncol. 2012;23:1499–502. https://doi.org/10.1093/annonc/mdr480.

    Article  CAS  PubMed  Google Scholar 

  9. Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase ii study of the intergroupe francophone du myelome. J Clin Oncol. 2016;34:2125–32. https://doi.org/10.1200/JCO.2015.63.1929.

    Article  CAS  PubMed  Google Scholar 

  10. Benson DM Jr, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma. 2007;48:1423–5. https://doi.org/10.1080/10428190701361851.

    Article  CAS  PubMed  Google Scholar 

  11. Guglielmelli T, Merlini R, Giugliano E, Saglio G. Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. J Oncol. 2009;2009:867380 https://doi.org/10.1155/2009/867380.

    Article  PubMed  PubMed Central  Google Scholar 

  12. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–81. https://doi.org/10.1056/NEJMoa1114083. e-pub ahead of print 2012/05/11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014;28:690–3. https://doi.org/10.1038/leu.2013.335. e-pub ahead of print 2013/11/14.

    Article  CAS  PubMed  Google Scholar 

  14. Andrzej Jakubowiak KG, Jasielec Jagoda, Rosenbaum Cara, McDonnell Kathryn, Berdeja Jesus.Vij Ravi,et al.Hematologica. 2015;100:312.

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Yale School of Medicine, New Haven, CT, 06511, USA

    Lohith Gowda

  2. Division of Hematologic Malignancies, Mayo Clinic, Rochester, MN, 55905, USA

    Mithun Shah

  3. Department of Stem Cell Transplant, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Ifra Badar, Qaiser Bashir, Rohtesh Mehta, Abdul Shah, Simrit Parmar, Yago Nieto, Richard Champlin & Muzaffar H. Qazilbash

  4. Division of Hematology, University of California San Francisco, San Francisco, CA, 94143, USA

    Nina Shah

  5. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Krina Patel, Donna M. Weber, Hans C. Lee, Elisabet E. Manasanch, Sheeba K. Thomas & Robert Z. Orlowski

  6. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA

    Rashmi Kanagal-Shamanna

Authors
  1. Lohith Gowda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mithun Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ifra Badar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qaiser Bashir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nina Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Krina Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rashmi Kanagal-Shamanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rohtesh Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Donna M. Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hans C. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Elisabet E. Manasanch
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Abdul Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sheeba K. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Simrit Parmar
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yago Nieto
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Robert Z. Orlowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Richard Champlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Muzaffar H. Qazilbash
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Muzaffar H. Qazilbash.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gowda, L., Shah, M., Badar, I. et al. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 54, 1089–1093 (2019). https://doi.org/10.1038/s41409-018-0392-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-018-0392-1

This article is cited by

Search

Advanced search

Quick links